
MIND PUBLICATIONS


MARIJUANA INVESTIGATIONS FOR NEUROSCIENTIFIC DISCOVERY
August 3, 2021
Cannabis
MIND is excited to share an advance online print of our article, which will soon be published in Cannabis, the official journal of the Research Society on Marijuana (RSMJ). Findings suggest that medical cannabis (MC) patients, who were followed over 12 months of MC treatment exhibit increased scores on the Cannabis Use Disorders Screening Test - Revised (CUDIT-R) relative to baseline (pre-treatment); however, increased CUDIT-R scores appear to be attributable to expected increases in frequency of MC use, rather than increases in more problematic symptoms/behaviors associated with cannabis use disorder (CUD). Further, increased CUDIT-R scores were related to higher THC exposure, but were not related to frequency of MC use overall or exposure to CBD. Importantly, preliminary analyses suggest that CUDIT-R may not be reliable or valid when used in MC patients. Accordingly, new metrics for assessing CUD in those who use cannabis for medical purposes are needed.
November 4, 2020
JAMA Psychiatry
We are excited to share that a set of findings from the open label phase of our clinical trial assessing a full-spectrum, high-CBD/low-THC product were recently published in JAMA Psychiatry! These findings show that 50% of individuals enrolled in the clinical trial tested positive for THC on a urinary drug assay after using the the sublingual solution for four weeks. Positive THC findings occurred in some individuals although the study product contains far less THC than is allowable for hemp-based products in the US. More research is needed to understand which variables may contribute to positive findings in some individuals, but not others.
July 15, 2021
Journal of the International Neuropsychological Society
We are pleased to announce that JINS has just published data from MIND's longitudinal study. This publication represents the first study to directly assess the longitudinal impact of medical cannabis (MC) on cognition and clinical variables in “real world” MC patients, who were assessed prior to initiating MC use and followed over the course of 1 year of treatment. Findings revealed that MC patients demonstrated significant improvements on measures of executive function and clinical state, while verbal learning/ memory performance generally remained stable relative to baseline. Improved cognitive performance was not correlated with MC use; however, clinical improvement was associated with higher CBD use.
Click below to read more, and don't forget to also check out some of the other interesting papers published in this JINS special issue, Clarifying the Complexities of Cannabis and Cognition, which was edited by Dr. Gruber and two of our IDEAA collaborators, Drs. Lisdahl and Filbey!
January 22, 2018
Frontiers in Pharmacology
We are pleased to announce that Frontiers has just published our second paper from the MIND program. This marks the first neuroimaging study in medical cannabis patients, and documents potential normalization of brain activity during the Multi-Source Interference Task (MSIT), a measure of executive function, after three months of medical cannabis treatment.
March 25, 2021
Experimental and Clinical Psychopharmacology
We are happy to announce that our newest paper was just published in the Journal of Experimental and Clinical Psychopharmacology. We recently completed analyses of medical cannabis (MC) patients who report chronic pain as their primary indication for MC use and compared them to a pilot sample of treatment-as-usual (TAU) patients who do not use MC. Results revealed that after initiation of MC use, MC patients generally exhibited lower self-reported pain ratings, which were accompanied by improvements on measures of clinical state, quality of life, and sleep - a pattern not observed in the TAU group. Among MC patients , increased THC exposure was related to pain-related improvement, while CBD exposure was related to improved mood.
October 13, 2016
Splendor in the grass? A pilot study assessing the impact of medical marijuana on executive function
Frontiers in Pharmacology
The first publication from the MIND program was published today in Frontiers in Pharmacology! After 3 months of medical cannabis treatment, medical cannabis patients demonstrated improvements in clinical state, cognition, quality of life and other health-related measures. Decreased use of conventional pharmaceutical medications was also noted among study patients.